TABLE 1.

Management of Allergen Immunotherapy practice during the COVID‐19 pandemic (Questions 9–11)

	Responses (n = 345)	%
Question 9. Are there any national consensus or position papers for the management of AIT during the COVID‐19 pandemic available in your country?
Yes	250	72.5
No	30	8.7
I Don't know	65	18.8
Question 10. Do you follow any national or international (e.g., EAACI, WHO, AAAAI) position paper/Consensus reports for the management of AIT during the COVID‐19 pandemic?
I don't know.	47	13.7
No, we're following a different strategy.	32	9.3
Yes, but we followed a similar strategy prior to knowing about the position papers.	235	68.3
Yes	30	8.7
Question 11. Which measures did you perform during the COVID‐19 lockdown or during pandemic‐related hardest restrictions for the management of your allergic patients?
Stop both first and follow‐up consultations	6	1.7
Replace face‐to‐face visits by phone calls for all patients	7	2
Replace face‐to‐face visits by phone calls for follow‐up, but to maintain face‐to‐face visits for new patients	9	2.6
Maintain face‐to‐face visits for all patients	255	73.9
Other	68	19.7

Abbreviations: AIT, allergen immunotherapy; AAAAI, American Academy of Allergy and Clinical Immunology; EAACI, European Academy of Allergy and Clinical Immunology; WHO, World Health Organisation.